AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
uridine triacetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| uridine derivatives used as antiviral agents and as antineoplastics | 5029 | 4105-38-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Uridine triacetate is an acetylated form of uridine. Following oral administration, uridine triacetate is deacetylated by nonspecific esterases present throughout the body, yielding uridine in the systemic circulation of patients with hereditary orotic aciduria who cannot synthesize adequate quantities of uridine due to a genetic defect in uridine nucleotide synthesis.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 8 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IGF1R,ITK,JAK1,JAK2,MAP3K21,MAP3K7,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PDK1,PDK2,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 52 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,GRK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,TEK | 10 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 4, 2015 | FDA | WELLSTAT THERAPEUTICS CORP |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Complication associated with device | 84.53 | 59.46 | 16 | 157 | 20057 | 110569069 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A16AX13 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Various alimentary tract and metabolism products |
| FDA Chemical/Ingredient | N0000007587 | Pyrimidines |
| FDA Chemical/Ingredient | N0000175452 | Analogs/Derivatives |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:49103 | drug metabolite |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| CHEBI has role | CHEBI:77746 | human metabolite |
| CHEBI has role | CHEBI:78675 | fundamental metabolite |
| FDA EPC | N0000191809 | Pyrimidine Analog |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:63726 | neuroprotective agent |
| CHEBI has role | CHEBI:71031 | orphan drug |
Related Drugs by ATC class:
A16AX Various alimentary tract and metabolism products 23 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hereditary orotic aciduria | indication | 16242007 | |
| Antimetabolite overdose | indication | 295696001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.68 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 10GM/PACKET | VISTOGARD | BTG INTL | N208159 | Dec. 11, 2015 | RX | GRANULE | ORAL | 7776838 | Aug. 17, 2027 | EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 2WP61F175M | UNII |
| 4035398 | VANDF |
| 4035399 | VANDF |
| C0281351 | UMLSCUI |
| CHEBI:90914 | CHEBI |
| URI | PDB_CHEM_ID |
| CHEMBL2107381 | ChEMBL_ID |
| 20058 | PUBCHEM_CID |
| DB09144 | DRUGBANK_ID |
| 9204 | INN_ID |
| C000609666 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB02745 | DRUGBANK_ID |
| 11017 | RXNORM |
| 237553 | MMSL |
| 238118 | MMSL |
| 31371 | MMSL |
| d05935 | MMSL |
| 005776 | NDDF |
| 016442 | NDDF |
| 57763003 | SNOMEDCT_US |
| 715619008 | SNOMEDCT_US |
| C0041984 | UMLSCUI |
| CHEMBL100259 | ChEMBL_ID |
| 58-96-8 | SECONDARY_CAS_RN |
| 6029 | PUBCHEM_CID |
| 4566 | IUPHAR_LIGAND_ID |
| D014529 | MESH_DESCRIPTOR_UI |
| WHI7HQ7H85 | UNII |
| CHEBI:16704 | CHEBI |
| 2WP61F175M | INXIGHT DRUGS |
| WHI7HQ7H85 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VISTOGARD | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50633-220 | GRANULE | 951 mg | ORAL | NDA | 25 sections |
| XURIDEN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50633-330 | GRANULE | 951 mg | ORAL | NDA | 26 sections |